DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury

Neuroscience

Volumn 113, Issue 4, 2002, Pages 857-869

  Venero, J L ^a   Santiago, M ^a   Tomas Camardiel M ^a   Matarredona, E R ^a   Cano, J ^a   Machado, A ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

AP 5; APDC; Apoptosis; DCG IV; Glutamic acid decarboxylase; LY 341495; NAAG

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 2 (2',2' DICARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 5 PHOSPHONOVALERIC ACID; 4 AMINOPYRROLIDINE 2,4 DICARBOXYLATE; ALPHA METHYL 4 CARBOXYPHENYLGLYCINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA FRAGMENT; DOPAMINE; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; MESSENGER RNA; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DNA DAMAGE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG TOXICITY; ENZYME LOCALIZATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INOTROPISM; MALE; MICRODIALYSIS; MICROGLIA; MOLECULAR BIOLOGY; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; CYCLOPROPANES; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCINE; MALE; MICROGLIA; NERVE DEGENERATION; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER;

EID: 0037056034     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00232-4     Document Type: Article

References (56)

1. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19:1999;1708-1716.
2. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1991;1649-1659.
3. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
4. Behrens M.M., Strasser U., Heidinger V., Lobner D., Yu S.P., McDonald J.W., Won M., Choi D.W. Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity. Neuropharmacology. 38:1999;1621-1630.
5. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. 18:1998;9594-9600.
6. Bruno V., Battaglia G., Copani A., D'Onofrio M., Di Iorio P., De Blasi A., Melchiorri D., Flor P.J., Nicoletti F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 21:2001;13-33.
7. Bruno V., Battaglia G., Copani A., Giffard R.G., Raciti G., Raffaele R., Shinozaki H., Nicoletti F. Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur. J. Neurosci. 7:1995;1906-1913.
8. Bruno V., Copani A., Battaglia G., Raffaele R., Shinozaki H., Nicoletti F. Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. Eur. J. Pharmacol. 256:1994;109-112.
9. Bruno V., Sureda F.X., Storto M., Casabona G., Caruso A., Knopfel T., Kuhn R., Nicoletti F. The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J. Neurosci. 17:1997;1891-1897.
10. Bruton R.K., Ge J., Barnes N.M. Group I mGlu receptor modulation of dopamine release in the rat striatum in vivo. Eur. J. Pharmacol. 369:1999;175-181.
11. Buisson A., Choi D.W. The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology. 34:1995;1081-1087.
12. Buisson A., Yu S.P., Choi D.W. DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons. Eur. J. Neurosci. 8:1996;138-143.
13. Chiamulera C., Albertini P., Valerio E., Reggiani A. Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur. J. Pharmacol. 216:1992;335-336.
14. Colwell C.S., Altemus K.L., Cepeda C., Levine M.S. Regulation of N-methyl-D-aspartate-induced toxicity in the neostriatum: a role for metabotropic glutamate receptors? Proc. Natl. Acad. Sci. USA. 93:1996;1200-1204.
15. Colwell C.S., Altemus K.L., Levine M.S. Metabotropic glutamate receptor activation selectively limits excitotoxic damage in the intact neostriatum. Brain Res. 726:1996;223-226.
16. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev Pharmacol. Toxicol. 37:1997;205-237.
17. Copani A., Bruno V., Battaglia G., Leanza G., Pellitteri R., Russo A., Stanzani S., Nicoletti F. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol. Pharmacol. 47:1995;890-897.
18. D'Onofrio M., Cuomo L., Battaglia G., Ngomba R.T., Storto M., Kingston A.E., Orzi F., De Blasi A., Di Iorio P., Nicoletti F., Bruno V. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem. 78:2001;435-445.
19. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - Implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
20. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulatemicroglial proliferation and function. J. Neurosci. 16:1996;2508-2521.
21. Erlander M.G., Tillakaratne N.J., Feldblum S., Patel N., Tobin A.J. Two genes encode distinct glutamate decarboxylases. Neuron. 7:1991;91-100.
22. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:1992;493-501.
23. Hayashi Y., Momiyama A., Takahashi T., Ohishi H., Ogawa-Meguro R., Shigemoto R., Mizuno N., Nakanishi S. Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb. Nature. 366:1993;687-690.
24. Holscher C., Gigg J., O'Maram S.M. Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Neurosci. Biobehav. Rev. 23:1999;399-410.
25. Jane D.E., Jones P.L., Pook P.C., Tse H.W., Watkins J.C. Actions of two new antagonists showing selectivity for different sub-types of metabotropic glutamate receptor in the neonatal rat spinal cord. Br. J. Pharmacol. 112:1994;809-816.
26. Lee M.Y., Deller T., Kirsch M., Frotscher M., Hofmann H.D. Differential regulation of ciliary neurotrophic factor (CNTF) and CNTF receptor alpha expression in astrocytes and neurons of the fascia dentata after entorhinal cortex lesion. J. Neurosci. 17:1997;1137-1146.
27. Matarredona E.R., Santiago M., Venero J.L., Cano J., Machado A. Group-II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP(+)-induced neurotoxicity along with brain-derived neurotrophic factor induction. J. Neurochem. 76:2001;351-360.
28. Miyamoto M., Ishida M., Shinozaki H. Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group-II metabotropic glutamate receptors against intraventricular kainate in the rat. Neuroscience. 77:1997;131-140.
29. Moldrich R.X., Giardina S.F., Beart P.M. Group II mGlu receptor agonists fail to protect against various neurotoxic insults induced in murine cortical, striatal and cerebellar granular pure neuronal cultures. Neuropharmacology. 41:2001;19-31.
30. Neale J.H., Bzdega T., Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 75:2000;443-452.
31. Ohno M., Watanabe S. Persistent increase in dopamine release following activation of metabotropic glutamate receptors in the rat nucleus accumbens. Neurosci. Lett. 200:1995;113-116.
32. Opitz T., Reymann K.G. (1S,3R)-ACPD protects synaptic transmission from hypoxia in hippocampal slices. Neuropharmacology. 32:1993;103-104.
33. Orlando L.R., Luthi-Carter R., Standaert D.G., Coyle J.T., Penney J.B. Jr., Young A.B. N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci. Lett. 236:1997;91-94.
34. Orlando L.R., Standaert D.G., Penney J.B. Jr., Young A.B. Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions. Neurosci. Lett. 202:1995;109-112.
35. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. Academic, London.
36. Pin J.P., Bockaert J. Get receptive to metabotropic glutamate receptors. Curr. Opin. Neurobiol. 5:1995;342-349.
37. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15:1995;3775-3787.
38. Radka S.F., Holst P.A., Fritsche M., Altar C.A. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res. 709:1996;122-301.
39. Raivich G., Bohatschek M., Kloss C.U., Werner A., Jones L.L., Kreutzberg G.W. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Rev. 30:1999;77-105.
40. Rouse S.T., Marino M.J., Bradley S.R., Awad H., Wittmann M., Conn P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther. 88:2000;427-435.
41. Santiago M., Westerink B.H. Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes. Naunyn-Schmiedebergs Arch. Pharmacol. 342:1990;407-414.
42. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. USA. 92:1995;8935-8939.
43. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38:1999;1431-1476.
44. Schwarcz R., Foster A.C., French E.D., Whetsell W.O. Jr., Kohler C. Excitotoxic models for neurodegenerative disorders. Life Sci. 35:1984;19-32.
45. Schwarcz R., Whetsell W.O. Jr., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:1983;316-318.
46. Small D.L., Monette R., Chakravarthy B., Durkin J., Barbe G., Mealing G., Morley P., Buchan A.M. Mechanisms of 1S,3R-ACPD-induced neuroprotection in rat hippocampal slices subjected to oxygen and glucose deprivation. Neuropharmacology. 35:1996;1037-1048.
47. Thomas A.G., Olkowski J.L., Slusher B.S. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation. Eur. J. Pharmacol. 426:2001;35-38.
48. Uyama Y., Ishida M., Shinozaki H. DCG-IV, a potent metabotropic glutamate receptor agonist, as an NMDA receptor agonist in the rat cortical slice. Brain Res. 752:1997;327-330.
49. Venero J.L., Beck K.D., Hefti F. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA. Neuroscience. 61:1994;256-257.
50. Venero J.L., Romero-Ramos M., Revuelta M., Machado A., Cano J. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system. Brain Res. 672:1995;153-158.
51. Verma A., Moghaddam B. Regulation of striatal dopamine release by metabotropic glutamate receptors. Synapse. 28:1998;220-226.
52. Wang Y., Qin Z.H., Nakai M., Chase T.N. Glutamate metabotropic receptor agonist 1S,3R-ACPD induces internucleosomal DNA fragmentation and cell death in rat striatum. Brain Res. 772:1997;45-56.
53. Westerink B.H., Damsma G., Rollema H., De Vries J.B., Horn A.S. Scope and limitations of in vivo brain dialysis: a comparison of its application to various neurotransmitter systems. Life Sci. 41:1987;1763-1776.
54. Wilsch V.W., Pidoplichko V.I., Opitz T., Shinozaki H., Reymann K.G. Metabotropic glutamate receptor agonist DCG-IV as NMDA receptor agonist in immature rat hippocampal neurons. Eur. J. Pharmacol. 262:1994;287-289.
55. Zhou F.C., Chiang Y.H. Excitochemical-induced trophic bridging directs axonal growth of transplanted neurons to distal target. Cell Transplant. 4:1995;103-112.
56. Zhou F.C., Chiang Y.H., Wang Y. Constructing a new nigrostriatal pathway in the Parkinsonian model with bridged neural transplantation in substantia nigra. J. Neurosci. 16:1996;6965-6974.